178042-35-8

Basic information

• Product Name: Benzenemethanol, 4-amino-a-(trifluoromethyl)-
• Synonyms: 1-(4-Amino-phenyl)-2,2,2-trifluoro-ethanol;benzenemethanol, 4-amino-α-(trifluoromethyl)
• CAS NO: 178042-35-8
• Molecular Formula: C8H8F3NO
• Molecular Weight: 191.153
• Mol File: 178042-35-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 4-amino-a-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 4-amino-a-(trifluoromethyl)-(178042-35-8)
• EPA Substance Registry System: Benzenemethanol, 4-amino-a-(trifluoromethyl)-(178042-35-8)

Safety Data

• Hazardous Substances Data: 178042-35-8(Hazardous Substances Data)

Upstream product

• 555-16-8 4-nitrobenzaldehdye 
• 241127-76-4 2,2,2-trifluoro-1-(4-nitrophenyl)ethan-1-ol 
• 552-89-6 2-nitro-benzaldehyde 
• 700362-32-9 2,2,2-trifluoro-1-(2-nitrophenyl) ethanol 
• 23516-79-2 4-(trifluoroacetyl)aniline 

Downstream Products

• 881992-39-8 5-(dimethylamino)naphthalene-1-sulfonic acid [4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]amide 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Fluorescence modulation in anion sensing by introducing intramolecular H-bonding interactions in host-guest adducts

Fluorescence signaling in anion binding is modulated from quenching to enhancement by intramolecular H-bonding stabilization of anion-ionophore adducts; the intramolecular H-bonding is suggested to suppress the quenching processes otherwise possible and i

Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs

Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the present invention, without limitation, satisfy either Formula 1 or Formula 2. Currently preferred compounds ,based on in vivo biological activity, are 4'-adamantylbenzoate-1'-N-1,4-dihydroxybenzylamine and 4'-adamantylmethylbenzoate-1'-N-1,4-dihydroxybenzylamine. The present invention also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs. Such compositions also may comprise other active ingredients, other materials conventionally used in the formulation of pharmaceutical composition, and mixtures thereof. The compounds and compositions of the present invention can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.